Cargando…
Formulation Patents and Dermatology and Obviousness
Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known pri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857063/ https://www.ncbi.nlm.nih.gov/pubmed/24309313 http://dx.doi.org/10.3390/pharmaceutics3040914 |
_version_ | 1782295111638450176 |
---|---|
author | Mei, Dan-Feng Liu, Josephine Davitz, Michael A. |
author_facet | Mei, Dan-Feng Liu, Josephine Davitz, Michael A. |
author_sort | Mei, Dan-Feng |
collection | PubMed |
description | Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known prior to the filing of the patent application. Because obviousness is an important concept in patent law, recent court cases concerning obviousness and formulation patents were examined and discussed below. Courts have ruled that patent claims are obvious when features of the claimed formulation are found in the prior art, even if the features or characteristics of the formulation are not explicitly disclosed in the prior art. However, patentees have successfully overcome obviousness challenges where there were unexpected results or properties and/or the prior art taught away from the claimed invention. |
format | Online Article Text |
id | pubmed-3857063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38570632013-12-16 Formulation Patents and Dermatology and Obviousness Mei, Dan-Feng Liu, Josephine Davitz, Michael A. Pharmaceutics Article Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known prior to the filing of the patent application. Because obviousness is an important concept in patent law, recent court cases concerning obviousness and formulation patents were examined and discussed below. Courts have ruled that patent claims are obvious when features of the claimed formulation are found in the prior art, even if the features or characteristics of the formulation are not explicitly disclosed in the prior art. However, patentees have successfully overcome obviousness challenges where there were unexpected results or properties and/or the prior art taught away from the claimed invention. MDPI 2011-11-21 /pmc/articles/PMC3857063/ /pubmed/24309313 http://dx.doi.org/10.3390/pharmaceutics3040914 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Mei, Dan-Feng Liu, Josephine Davitz, Michael A. Formulation Patents and Dermatology and Obviousness |
title | Formulation Patents and Dermatology and Obviousness |
title_full | Formulation Patents and Dermatology and Obviousness |
title_fullStr | Formulation Patents and Dermatology and Obviousness |
title_full_unstemmed | Formulation Patents and Dermatology and Obviousness |
title_short | Formulation Patents and Dermatology and Obviousness |
title_sort | formulation patents and dermatology and obviousness |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857063/ https://www.ncbi.nlm.nih.gov/pubmed/24309313 http://dx.doi.org/10.3390/pharmaceutics3040914 |
work_keys_str_mv | AT meidanfeng formulationpatentsanddermatologyandobviousness AT liujosephine formulationpatentsanddermatologyandobviousness AT davitzmichaela formulationpatentsanddermatologyandobviousness |